Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$1B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Editas Medicine
Editas Medicine is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. CRISPR-based gene editing company focused on inherited eye diseases. With a $1B market capitalization and no current profitability, Editas Medicine has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Unlock Full EDIT Analysis
Expert analysis and coverage for Editas Medicine
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.